Free Trial
→ I have publicly predicted six major American crashes, before each one happened. (From Weiss Ratings) (Ad)tc pixel
NASDAQ:OLMA

Olema Pharmaceuticals Q3 2026 Earnings Date & Estimates

Olema Pharmaceuticals logo
$6.74 -0.28 (-3.99%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Olema Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Olema Pharmaceuticals in Q3 2026

Olema Pharmaceuticals is expected to post earnings of -$0.60 per share on revenue of $1.25 million. In the same quarter a year earlier Olema Pharmaceuticals reported -$0.49 per share. Olema Pharmaceuticals last reported on August 10, 2026, posting -$0.61 per share and missing the -$0.5515 consensus estimate. Olema Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.60
Expected Revenue
$1.25 million
Prior-Year EPS
-$0.49

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.61 (Missed by -$0.0585)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Olema Pharmaceuticals Q3 2026 Earnings FAQ

Olema Pharmaceuticals (NASDAQ:OLMA) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Olema Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Olema Pharmaceuticals to post earnings of -$0.60 per share for Q3 2026.

The consensus revenue estimate for Olema Pharmaceuticals is $1.25 million for Q3 2026.

Olema Pharmaceuticals Earnings Headlines

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374040/0/en/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Olema Pharmaceuticals (OLMA) Receives a Rating Update from a Top Analyst
September 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OLMA/pressreleases/4724558/olema-pharmaceuticals-olma-receives-a-rating-update-from-a-top-analyst/
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
Stifel Nicolaus Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OLMA/pressreleases/4609019/stifel-nicolaus-sticks-to-their-buy-rating-for-olema-pharmaceuticals-olma/
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946694-olema-pharmaceuticals-inc-olma-presents-at-morgan-stanley-24th-annual-global-healthcare
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/olema-pharmaceuticals-shares-fall-15-121047397.html
See More Olema Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email.

About Olema Pharmaceuticals

Olema Pharmaceuticals (NASDAQ:OLMA) (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, with an emphasis on hormone receptor-positive breast cancer. The company’s research is centered on oral endocrine medicines designed to target estrogen receptor signaling, an important driver of many breast tumors.

Olema’s lead product candidate is palazestrant, an investigational oral selective estrogen receptor degrader (SERD) being evaluated for the treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The company is studying palazestrant as a potential treatment both on its own and in combination with other anticancer therapies.

Founded in 2013 and headquartered in San Francisco, Olema conducts drug discovery and clinical development activities through research programs and clinical studies intended to support regulatory approval in major international markets. As a clinical-stage company, its products remain investigational and are not yet approved for commercial use.

View Olema Pharmaceuticals Profile
Earnings Tools